NeoSan Pharma is engaged in the scientific research, development, and commercialization of innovative medical solutions for infectious disease.
Over 2.8 million people get infections caused by antibiotic-resistant bacteria each year. 35,000 people die from these evolved strains in the U.S. alone. When a bacteria evolves mechanisms against more than one antibiotic, we are dealing with “Multidrug-Resistant Bacteria.” These bacterial pathogens present two challenges, they are difficult to treat and they can help other bacteria develop multidrug resistance, enabling them to spread even further.
We don’t see multidrug-resistant pathogens as a barrier,
we think of them as a good place to start.
MRSA stands for Methicillin-Resistant Staphylococcus Aureus, a type of bacteria that is resistant to several antibiotics. MRSA most often causes skin infections, in some cases pneumonia (lung infection), bloodstream, and surgical site infections. If left untreated, MRSA infections can become severe and cause sepsis—the body’s extreme response to an infection.
Our scientist are in advanced developmental stages of a prescription-strength, single-dose topical treatment against multidrug-resistant bacteria, including MRSA.
